<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LUPRON - leuprolide acetate 
			 </strong><br><strong>LUPRON- leuprolide acetate injection, solution </strong><br>TAP Pharmaceutical Products Inc.<br></p></div>
<h1>LUPRON<span class="Sup">®</span> INJECTION<br>(leuprolide acetate)</h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-3"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Leuprolide acetate is a synthetic nonapeptide analog of naturally occurring gonadotropin releasing hormone (GnRH or LH-RH).  The analog possesses greater potency than the natural hormone.  The chemical name is 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide acetate (salt) with the following structural formula:</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=319F0AF7-6CC7-4A91-A28A-9CEEA37D0CA8&amp;name=luproninjection-01.jpg"></div>
<p>LUPRON INJECTION is a sterile, aqueous solution intended for subcutaneous injection.  It is available in a 2.8 mL multiple-dose vial containing leuprolide acetate (5 mg/mL), sodium chloride, USP (6.3 mg/mL) for tonicity adjustment, benzyl alcohol, NF as a preservative (9 mg/mL), and water for injection, USP.  The pH may have been adjusted with sodium hydroxide, NF and/or acetic acid, NF.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-4"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Leuprolide acetate, an LH-RH agonist, acts as a potent inhibitor of gonadotropin secretion when given continuously and in therapeutic doses.  Animal and human studies indicate that following an initial stimulation of gonadotropins, chronic administration of leuprolide acetate results in suppression of ovarian and testicular steroidogenesis.  This effect is reversible upon discontinuation of drug therapy. Administration of leuprolide acetate has resulted in inhibition of the growth of certain hormone dependent tumors (prostatic tumors in Noble and Dunning male rats and DMBA-induced mammary tumors in female rats) as well as <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> of the reproductive organs.</p>
<p>In humans, subcutaneous administration of single daily doses of leuprolide acetate results in an initial increase in circulating levels of luteinizing hormone (LH) and follicle stimulating hormone (FSH), leading to a transient increase in levels of the gonadal steroids (testosterone and dihydrotestosterone in males, and estrone and estradiol in pre-menopausal females).  However, continuous daily administration of leuprolide acetate results in decreased levels of LH and FSH.  In males, testosterone is reduced to castrate levels. In pre-menopausal females, estrogens are reduced to post-menopausal levels. These decreases occur within two to four weeks after initiation of treatment, and castrate levels of testosterone in prostatic cancer patients have been demonstrated for periods of up to five years.</p>
<p>Leuprolide acetate is not active when given orally.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="Pharmacokinetics"></a><a name="section-4.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1.1"></a><p></p>
<h3>Absorption </h3>
<p class="First">Bioavailability by subcutaneous administration is comparable to that by intravenous administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1.2"></a><p></p>
<h3>Distribution </h3>
<p class="First">The mean steady-state volume of distribution of leuprolide following intravenous bolus administration to healthy male volunteers was 27 L. <span class="Italics">In vitro</span> binding to human plasma proteins ranged from 43% to 49%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1.3"></a><p></p>
<h3>Metabolism </h3>
<p class="First">In healthy male volunteers, a 1 mg bolus of leuprolide administered intravenously revealed that the mean systemic clearance was 7.6 L/h, with a terminal elimination half-life of approximately 3 hours based on a two compartment model. In rats and dogs, administration of <span class="Sup">14</span>C-labeled leuprolide was shown to be metabolized to smaller inactive peptides, a pentapeptide (Metabolite I), tripeptides (Metabolites II and III) and a dipeptide (Metabolite IV). These fragments may be further catabolized.</p>
<p>The major metabolite (M-I) plasma concentrations measured in 5 prostate cancer patients reached maximum concentration 2 to 6 hours after dosing and were approximately 6% of the peak parent drug concentration. One week after dosing, mean plasma M-I concentrations were approximately 20% of mean leuprolide concentrations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1.4"></a><p></p>
<h3>Excretion </h3>
<p class="First">Following administration of LUPRON DEPOT 3.75 mg to 3 patients, less than 5% of the dose was recovered as parent and M-I metabolite in the urine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1.5"></a><p></p>
<h3>Special Populations </h3>
<p class="First">The pharmacokinetics of the drug in hepatically and renally impaired patients has not been determined. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1.6"></a><p></p>
<h3>Drug Interactions </h3>
<p class="First">No pharmacokinetic-based drug-drug interaction studies have been conducted with leuprolide acetate. However, because leuprolide acetate is a peptide that is primarily degraded by peptidase and not by cytochrome P-450 enzymes as noted in specific studies, and the drug is only about 46% bound to plasma proteins, drug interactions would not be expected to occur.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-5"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">In a controlled study comparing LUPRON 1 mg/day given subcutaneously to DES (diethylstilbestrol), 3 mg/day, the survival rate for the two groups was comparable after two years of treatment.  The objective response to treatment was also similar for the two groups.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-6"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">LUPRON INJECTION (leuprolide acetate) is indicated in the palliative treatment of advanced prostatic cancer.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Contraindications"></a><a name="section-7"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<ol>
<li>LUPRON INJECTION is contraindicated in patients known to be hypersensitive to GnRH, GnRH agonist analogs or any of the excipients in LUPRON INJECTION: Reports of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> to GnRH agonist analogs have been reported in the medical literature.<span class="Sup">1,2</span>
</li>
<li>LUPRON is contraindicated in women who are or may become pregnant while receiving the drug. LUPRON may cause fetal harm when administered to a pregnant woman. Therefore, the possibility exists that <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortion</span> may occur if the drug is administered during pregnancy. If this drug is administered during pregnancy or if the patient becomes pregnant while taking any formulation of LUPRON, the patient should be apprised of the potential hazard to the fetus.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Warnings"></a><a name="section-8"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Initially, LUPRON, like other LH-RH agonists, causes increases in serum levels of testosterone.  Transient worsening of symptoms, or the occurrence of additional signs and symptoms of prostate cancer, may occasionally develop during the first few weeks of LUPRON treatment. A small number of patients may experience a temporary increase in <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span>, which can be managed symptomatically. As with other LH-RH agonists, isolated cases of ureteral obstruction and <span class="product-label-link" type="condition" conceptid="4322945" conceptname="Spinal cord compression">spinal cord compression</span> have been observed, which may contribute to <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> with or without fatal complications.</p>
<p>Safe use of leuprolide acetate in pregnancy has not been established clinically. Before starting treatment with LUPRON, pregnancy must be excluded (see <span class="Bold"><a href="#Contraindications">CONTRAINDICATIONS</a></span> section). </p>
<p>Periodic monitoring of serum testosterone and prostate-specific antigen (PSA) levels is recommended, especially if the anticipated clinical or biochemical response to treatment has not been achieved. It should be noted that results of testosterone determinations are dependent on assay methodology. It is advisable to be aware of the type and precision of the assay methodology to make appropriate clinical and therapeutic decisions.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-9"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">Patients with metastatic vertebral lesions and/or with <span class="product-label-link" type="condition" conceptid="194406" conceptname="Urinary tract obstruction">urinary tract obstruction</span> should be closely observed during the first few weeks of therapy (see <span class="Bold"><a href="#Warnings">WARNINGS</a></span> and <span class="Bold"><a href="#Adverse_Reactions">ADVERSE REACTIONS</a></span> sections).</p>
<p>Patients with known allergies to benzyl alcohol, an ingredient of the drug's vehicle, may present symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, usually local, in the form of <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> and <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span> at the injection site.</p>
<div class="Section" data-sectionCode="34076-0">
<a name="section-9.1"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">See <span class="Bold"><a href="#Information_Patients">INFORMATION FOR PATIENTS</a></span> which appears after the <span class="Bold">REFERENCE</span> section.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-9.2"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Response to leuprolide acetate should be monitored by measuring serum levels of testosterone and prostate-specific antigen (PSA).  In the majority of patients, testosterone levels increased above baseline during the first week, declining thereafter to baseline levels or below by the end of the second week of treatment.  Castrate levels were reached within two to four weeks and once attained were maintained for as long as drug administration continued.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-9.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">See <span class="Bold"><a href="#Pharmacokinetics">CLINICAL PHARMACOLOGY, Pharmacokinetics</a></span> section.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section-9.4"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">Administration of leuprolide acetate in therapeutic doses results in suppression of the pituitary-gonadal system.  Normal function is usually restored within 4 to 12 weeks after treatment is discontinued.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-9.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Two-year carcinogenicity studies were conducted in rats and mice.  In rats, a dose-related increase of benign pituitary <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> and benign <span class="product-label-link" type="condition" conceptid="437251" conceptname="Benign neoplasm of pituitary gland and craniopharyngeal duct">pituitary adenomas</span> was noted at 24 months when the drug was administered subcutaneously at high daily doses (0.6 to 4 mg/kg).  There was a significant but not dose-related increase of pancreatic islet-cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in females and of testicular interstitial cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in males (highest incidence in the low dose group). In mice no pituitary abnormalities were observed at a dose as high as 60 mg/kg for two years.  Patients have been treated with leuprolide acetate for up to three years with doses as high as 10 mg/day and for two years with doses as high as 20 mg/day without demonstrable pituitary abnormalities.</p>
<p>Mutagenicity studies have been performed with leuprolide acetate using bacterial and mammalian systems.  These studies provided no evidence of a mutagenic potential.</p>
<p>Clinical and pharmacologic studies in adults (≥ 18 years) with leuprolide acetate and similar analogs have shown full reversibility of fertility suppression when the drug is discontinued after continuous administration for periods of up to 24 weeks.  However, no clinical studies have been conducted with leuprolide acetate to assess the reversibility of fertility suppression.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-9.6"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-9.6.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.6.1.1"></a><p></p>
<h4>Pregnancy Category X</h4>
<p class="First">(see <span class="Bold"><a href="#Contraindications">CONTRAINDICATIONS</a></span> and <span class="Bold"><a href="#Warnings">WARNINGS</a></span> sections)</p>
<p> When administered on day 6 of pregnancy at test dosages of 0.00024, 0.0024, and 0.024 mg/kg (1/600 to 1/6 the human dose) to rabbits, LUPRON produced a dose-related increase in major fetal abnormalities. Similar studies in rats failed to demonstrate an increase in major <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> throughout gestation. There was increased fetal mortality and decreased fetal weights with the two higher doses of LUPRON in rabbits and with the highest dose in rats. The effects on fetal mortality are expected consequences of the alterations in hormonal levels brought about by this drug.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-9.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether leuprolide acetate is excreted in human milk. LUPRON should not be used by nursing mothers.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-9.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">See labeling for <a href="#For_Ped_Use">LUPRON INJECTION for Pediatric Use</a> for the safety and effectiveness in children with central <span class="product-label-link" type="condition" conceptid="4267558" conceptname="Precocious puberty">precocious puberty</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-9.9"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">In the clinical trials for LUPRON INJECTION, the majority (69%) of subjects studied were at least 65 years of age.  Therefore, the labeling reflects the pharmacokinetics, efficacy and safety of LUPRON in this population.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Adverse_Reactions"></a><a name="section-10"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2>Clinical Trials</h2>
<p class="First">In the majority of patients testosterone levels increased above baseline during the first week, declining thereafter to baseline levels or below by the end of the second week of treatment.  This transient increase was occasionally associated with a temporary worsening of signs and symptoms, usually manifested by an increase in <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span> (see <span class="Bold"><a href="#Warnings">WARNINGS</a></span> section).  In a few cases a temporary worsening of existing <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> and <span class="product-label-link" type="condition" conceptid="194406" conceptname="Urinary tract obstruction">urinary tract obstruction</span> occurred during the first week. Temporary <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> of the lower limbs have been reported in a few cases.</p>
<p>Potential exacerbations of signs and symptoms during the first few weeks of treatment is a concern in patients with vertebral <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> and/or urinary obstruction which, if aggravated, may lead to neurological problems or increase the obstruction.</p>
<p>In a comparative trial of LUPRON INJECTION (leuprolide acetate) versus DES, in 5% or more of the patients receiving either drug, the following adverse reactions were reported to have a possible or probable relationship to drug as ascribed by the treating physician.  Often, causality is difficult to assess in patients with metastatic prostate cancer.  Reactions considered not drug related are excluded.</p>
<table width="75%">
<col align="left" width="64%">
<col align="center" width="18%">
<col align="center" width="18%">
<thead>
<tr class="First">
<th align="left"></th>
<th align="center">LUPRON<br><span class="Underline">(N=98)</span>
</th>
<th align="center">DES<br><span class="Underline">(N=101)</span>
</th>
</tr>
<tr class="Last">
<th align="left"></th>
<th align="center" colspan="2"><span class="Underline">Number of Reports</span></th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Physiologic effect of decreased testosterone.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left">Cardiovascular System</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span></td>
<td align="center">1</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left">  ECG changes/<span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span></td>
<td align="center">19</td>
<td align="center">22</td>
</tr>
<tr>
<td align="left">  High blood pressure</td>
<td align="center">8</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left">  Murmur</td>
<td align="center">3</td>
<td align="center">8</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span></td>
<td align="center">12</td>
<td align="center">30</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">Phlebitis</span>/<span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span></td>
<td align="center">2</td>
<td align="center">10</td>
</tr>
<tr>
<td align="left">Gastrointestinal System</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td align="center">6</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td align="center">7</td>
<td align="center">9</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></td>
<td align="center">5</td>
<td align="center">17</td>
</tr>
<tr>
<td align="left">Endocrine System</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>Decreased testicular size</td>
<td align="center">7</td>
<td align="center">11</td>
</tr>
<tr>
<td align="left">  <a href="#footnote-1" class="Sup">*</a><span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span>/<span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">breast tenderness</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></td>
<td align="center">7</td>
<td align="center">63</td>
</tr>
<tr>
<td align="left">  <a href="#footnote-1" class="Sup">*</a><span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot flashes</span></td>
<td align="center">55</td>
<td align="center">12</td>
</tr>
<tr>
<td align="left">  <a href="#footnote-1" class="Sup">*</a><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span></td>
<td align="center">4</td>
<td align="center">12</td>
</tr>
<tr>
<td align="left">Hemic and Lymphatic System</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td align="center">5</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left">Musculoskeletal System</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">Bone pain</span></td>
<td align="center">5</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td align="center">3</td>
<td align="center">9</td>
</tr>
<tr>
<td align="left">Central/Peripheral Nervous System</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>/<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span></td>
<td align="center">5</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">  General <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></td>
<td align="center">13</td>
<td align="center">13</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center">7</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span>/<span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorders</span></td>
<td align="center">7</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left">Respiratory System</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td align="center">2</td>
<td align="center">8</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4220211" conceptname="Congestion of nasal sinus">Sinus congestion</span></td>
<td align="center">5</td>
<td align="center">6</td>
</tr>
<tr>
<td align="left">Integumentary System</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Dermatitis</span></td>
<td align="center">5</td>
<td align="center">8</td>
</tr>
<tr>
<td align="left">Urogenital System</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  Frequency/urgency</td>
<td align="center">6</td>
<td align="center">8</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span></td>
<td align="center">6</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></td>
<td align="center">3</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">Miscellaneous</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr class="Last">
<td align="left">  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td align="center">10</td>
<td align="center">10</td>
</tr>
</tbody>
</table>
<p>In this same study, the following adverse reactions were reported in less than 5% of the patients on LUPRON.</p>
<p><span class="Italics">Cardiovascular System</span>—Angina, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Cardiac arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span>, Pulmonary emboli; <span class="Italics">Gastrointestinal System</span>—<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal bleeding</span>, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disturbance</span>, <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">Peptic ulcer</span>, <span class="product-label-link" type="condition" conceptid="4216644" conceptname="Rectal polyp">Rectal polyps</span>; <span class="Italics">Endocrine System</span>—Libido decrease, Thyroid enlargement; <span class="Italics">Musculoskeletal System</span>—<span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Joint pain</span>; <span class="Italics">Central/Peripheral Nervous System</span>—<span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span>, Memory disorder, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">Mood swings</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>/<span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">blackouts</span>, Taste disorders; <span class="Italics">Respiratory System</span>—<span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span>, <span class="product-label-link" type="condition" conceptid="4291941" conceptname="Pleural friction rub">Pleural rub</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span>, <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">Pulmonary fibrosis</span>; <span class="Italics">Integumentary System</span>—Carcinoma of skin/ear, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Dry skin</span>, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">Ecchymosis</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Hair loss</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">Itching</span>, Local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">Pigmentation</span>, <span class="product-label-link" type="condition" conceptid="4316083" conceptname="Skin lesion">Skin lesions</span>; <span class="Italics">Urogenital System</span>—<span class="product-label-link" type="condition" conceptid="4090870" conceptname="Spasm of bladder">Bladder spasms</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">Dysuria</span>, <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">Incontinence</span>, <span class="product-label-link" type="condition" conceptid="4270932" conceptname="Pain in testicle">Testicular pain</span>, Urinary obstruction; <span class="Italics">Miscellaneous</span>—<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>/<span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span>, Increased BUN, Increased calcium, Increased creatinine, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>/<span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, Ophthalmologic disorders, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">Swelling</span> (temporal bone).</p>
<p>In an additional clinical trial and from long-term observation of both studies, the following additional adverse events (excluding those considered not drug related) were reported for patients receiving LUPRON.</p>
<p><span class="Italics">Cardiovascular System</span>—<span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="4304563" conceptname="Carotid bruit">Carotid bruit</span>, Extrasystole, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span>, Perivascular cuffing (eyes), Ruptured <span class="product-label-link" type="condition" conceptid="317585" conceptname="Aortic aneurysm">aortic aneurysm</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span>, Transient ischemic attack; <span class="Italics">Gastrointestinal System</span>—<span class="product-label-link" type="condition" conceptid="4091513" conceptname="Passing flatus">Flatus</span>, Dryness of mouth and throat, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span>, <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span>, Occult blood (rectal exam), <span class="product-label-link" type="condition" conceptid="193807" conceptname="Anorectal fistula">Rectal fistula</span>/<span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>; <span class="Italics">Endocrine System</span>—Libido increase, <span class="product-label-link" type="condition" conceptid="4030041" conceptname="Thyroid nodule">Thyroid nodule</span>; <span class="Italics">Musculoskeletal System</span>—Ankylosing <span class="product-label-link" type="condition" conceptid="74130" conceptname="Thoracic spondylosis without myelopathy">spondylosis</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span>, Blurred disc margins, Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">Muscle stiffness</span>, Muscle <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, <span class="product-label-link" type="condition" conceptid="4318540" conceptname="Fibrosis of pelvic cavity">Pelvic fibrosis</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Spasms</span>/<span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>; <span class="Italics">Central/Peripheral Nervous System</span>—<span class="product-label-link" type="condition" conceptid="4164151" conceptname="Auditory hallucinations">Auditory hallucinations</span>/<span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, Decreased hearing, Decreased reflexes, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">Euphoria</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">Hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="4185711" conceptname="Loss of sense of smell">Loss of smell</span>, Motor deficiency; <span class="Italics">Respiratory System</span>—<span class="product-label-link" type="condition" conceptid="4034235" conceptname="Tight chest">Chest tightness</span>, Decreased breathing sounds, <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">Hemoptysis</span>, Pleuritic <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>,   Pulmonary infiltrate, <span class="product-label-link" type="condition" conceptid="4167669" conceptname="Respiratory crackles">Rales</span>/<span class="product-label-link" type="condition" conceptid="4084392" conceptname="Wheeze - rhonchi">rhonchi</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span>, Strep throat, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">Wheezing</span>/<span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>; <span class="Italics">Integumentary System</span>—<span class="product-label-link" type="condition" conceptid="4220002" conceptname="Furuncle">Boil</span> (pubic), <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">Bruises</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Hives</span>, <span class="product-label-link" type="condition" conceptid="4098436" conceptname="Hyperkeratosis">Keratosis</span>, Mole, <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Shingles</span>, Spiders; <span class="Italics">Urogenital System</span>— <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blisters</span> on penis, <span class="product-label-link" type="condition" conceptid="4288544" conceptname="Inguinal hernia">Inguinal hernia</span>, <span class="product-label-link" type="condition" conceptid="4224222" conceptname="Penile swelling">Penile swelling</span>, Post void residual, <span class="product-label-link" type="condition" conceptid="4280580" conceptname="Prostatic pain">Prostatic pain</span>, <span class="product-label-link" type="condition" conceptid="4167328" conceptname="Pyuria">Pyuria</span>; <span class="Italics">Miscellaneous</span>—Abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, <span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">Facial swelling</span>/<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, Feet burning, Flu, Eyelid growth, <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">Hypoproteinemia</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Accidental injury</span>, <span class="product-label-link" type="condition" conceptid="72407" conceptname="Effusion of joint of shoulder region">Knee effusion</span>, <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">Mass</span>, Pallid, Sallow, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2>Postmarketing </h2>
<p class="First">During postmarketing surveillance which includes other dosage forms and other patient populations, the following adverse events were reported.</p>
<p>Symptoms consistent with an anaphylactoid or <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> process have been rarely (incidence rate of about 0.002%) reported. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reactions</span> have also been reported. </p>
<p>Localized reactions including <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span> and <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span> have been reported at the site of injection.</p>
<p>Symptoms consistent with <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span> (e.g., joint and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorders</span>, gastrointestinal distress, and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>) have been reported individually and collectively.</p>
<p><span class="Italics">Cardiovascular System</span> – <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span>; <span class="Italics">Endocrine System</span> - <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span>; <span class="Italics">Gastrointestinal System</span> – Hepatic dysfunction; <span class="Italics">Hemic and Lymphatic System</span> – Decreased WBC; <span class="Italics">Integumentary System</span> – Hair growth; <span class="Italics">Central/Peripheral Nervous System</span> – <span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">Spinal fracture</span>/<span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>, Hearing disorder; <span class="Italics">Miscellaneous</span> –  Hard <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodule</span> in throat, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span>, Increased uric acid; <span class="Italics">Musculoskeletal System</span> – <span class="product-label-link" type="condition" conceptid="4195698" conceptname="Tenosynovitis">Tenosynovitis</span>-like symptoms; <span class="Italics">Respiratory System</span> – <span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory disorders</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics">Changes in Bone Density:</span> Decreased bone density has been reported in the medical literature in men who have had orchiectomy or who have been treated with an LH-RH agonist analog. In a clinical trial, 25 men with prostate cancer, 12 of whom had been treated previously with leuprolide acetate for at least six months, underwent bone density studies as a result of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. The leuprolide-treated group had lower bone density scores than the nontreated control group. It can be anticipated that long periods of medical castration in men will have effects on bone density. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2.2"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4129534" conceptname="Pituitary apoplexy">Pituitary apoplexy</span>:</span> During post-marketing surveillance, rare cases of <span class="product-label-link" type="condition" conceptid="4129534" conceptname="Pituitary apoplexy">pituitary apoplexy</span> (a clinical syndrome secondary to <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> of the pituitary gland) have been reported after the  administration of gonadotropin-releasing hormone agonists.  In a majority of these cases, a <span class="product-label-link" type="condition" conceptid="437251" conceptname="Benign neoplasm of pituitary gland and craniopharyngeal duct">pituitary adenoma</span> was diagnosed, with a majority of <span class="product-label-link" type="condition" conceptid="4129534" conceptname="Pituitary apoplexy">pituitary apoplexy</span> cases occurring within 2 weeks of the first dose, and some within the first hour.  In these cases, <span class="product-label-link" type="condition" conceptid="4129534" conceptname="Pituitary apoplexy">pituitary apoplexy</span> has presented as sudden <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, visual changes, <span class="product-label-link" type="condition" conceptid="4052337" conceptname="Ophthalmoplegia">ophthalmoplegia</span>, altered mental status, and sometimes <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>.  Immediate medical attention has been required.</p>
<p>See other LUPRON DEPOT and LUPRON INJECTION package inserts for other events reported in the same and different patient populations.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-11"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">In rats subcutaneous administration of 250 to 500 times the recommended human dose, expressed on a per body weight basis, resulted in <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4139968" conceptname="Underactive">decreased activity</span>, and local irritation at the injection site. There is no evidence at present that there is a clinical counterpart of this phenomenon.  In early clinical trials with leuprolide acetate doses as high as 20 mg/day for up to two years caused no adverse effects differing from those observed with the 1 mg/day dose.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-12"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended dose is 1 mg (0.2 mL or 20 unit mark) administered as a single daily subcutaneous injection.  As with other drugs administered chronically by subcutaneous injection, the injection site should be varied periodically.  Each 0.2 mL contains 1 mg of leuprolide acetate, sodium chloride for tonicity adjustment, 1.8 mg of benzyl alcohol as preservative and water for injection. The pH may have been adjusted with sodium hydroxide and/or acetic acid.</p>
<p>Follow the pictorial directions on the reverse side of this package insert for administration.</p>
<p>NOTE:  As with all parenteral products, inspect the solution for discoloration and particulate matter before each use.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-13"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">LUPRON INJECTION (leuprolide acetate) is a sterile solution supplied in a 2.8 mL multiple-dose vial. The vial is packaged as follows: 14 Day Patient Administration Kit with 14 disposable syringes and 28 alcohol swabs, NDC 0300-3612-28 and six-vial carton, NDC 0300-3612-24. </p>
<p>Store below 77°F (25°C). Do not freeze. Protect from light; store vial in carton until use.</p>
<p>U.S. Patent Nos. 4,005,063 and 4,005,194.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-14"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>Taylor, JD. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reaction</span> to LHRH analogue, leuprorelin. <span class="Italics">Med J Australia</span> 1994 Oct; 161(3): 455.</li>
<li>Letterie GS, <span class="Italics">et al</span>. Recurrent <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> to a depot form of GnRH analogue. <span class="Italics">Obstet Gynecol</span> 1991 Nov; 78: 943–946.</li>
</ol>
</div>
<div class="Section" data-sectionCode="38056-8">
<a name="section-15"></a><p></p>
<div class="Section" data-sectionCode="42230-3">
<a name="Information_Patients"></a><a name="section-15.1"></a><p></p>
<h2>INFORMATION FOR PATIENTS</h2>
<p class="First">Be sure to consult your physician with any questions you may have or for information about LUPRON INJECTION (leuprolide acetate) and its use.</p>
<p><span class="Bold">WHAT IS LUPRON?</span></p>
<p>LUPRON INJECTION (leuprolide acetate) is chemically similar to gonadotropin releasing hormone (GnRH or LH-RH) a hormone which occurs naturally in your body.</p>
<p>Normally, your body releases small amounts of LH-RH and this leads to events which stimulate the production of sex hormones.</p>
<p>However, when you inject LUPRON INJECTION (leuprolide acetate), the normal events that lead to sex hormone production are interrupted and testosterone is no longer produced by the testes.</p>
<p>LUPRON must be injected because, like insulin which is injected by diabetics, LUPRON is inactive when taken by mouth.</p>
<p>If you were to discontinue the drug for any reason, your body would begin making testosterone again.</p>
<p><span class="Bold">DIRECTIONS FOR USING LUPRON</span></p>
<ol>
<li>Wash hands thoroughly with soap and water.</li>
<li>If using a new bottle for the first time, flip off the plastic cover to expose the grey rubber stopper.  Wipe metal ring and rubber stopper with an alcohol wipe each time you use LUPRON.  Check the liquid in the container.  If it is not clear or has particles in it, DO NOT USE IT.  Exchange it at your pharmacy for another container.</li>
<li>Remove outer wrapping from one syringe.  Pull plunger back until the tip of the plunger is at the 0.2 mL or 20 unit mark.</li>
<li>Take cover off needle.  Push the needle through the center of the rubber stopper on the LUPRON bottle.</li>
<li>Push the plunger all the way in to inject air into the bottle.</li>
<li>Keep the needle in the bottle and turn the bottle upside down.  Check to make sure the tip of the needle is in the liquid.  Slowly pull back on the plunger, until the syringe fills to the 0.2 mL or 20 unit mark.</li>
<li>Toward the end of a two-week period, the amount of LUPRON left in the bottle will be small.  Take special care to hold the bottle straight and to keep the needle tip in liquid while pulling back on the plunger.</li>
<li>Keeping the needle in the bottle and the bottle upside down, check for air bubbles in the syringe.  If you see any, push the plunger <span class="Italics">slowly</span> in to push the air bubble back into the bottle.  Keep the tip of the needle in the liquid and pull the plunger back again to fill to the 0.2 mL or 20 unit mark.</li>
<li>Do this again if necessary to eliminate air bubbles.</li>
<li>To protect your skin, inject each daily dose at a different body spot.</li>
<li>Choose an injection spot.  Cleanse the injection spot with another alcohol wipe.</li>
<li>Hold the syringe in one hand.  Hold the skin taut, or pull up a little flesh with the other hand, as you were instructed.</li>
<li>Holding the syringe as you would a pencil, thrust the needle all the way into the skin at a 90° angle.  Push the plunger to administer the injection.</li>
<li>Hold an alcohol wipe down on your skin where the needle is inserted and withdraw the needle at the same angle it was inserted.</li>
<li>Use the disposable syringe only once and dispose of it properly as you were instructed.  Needles thrown into a garbage bag could accidentally stick someone.  NEVER LEAVE SYRINGES, NEEDLES OR DRUGS WHERE CHILDREN CAN REACH THEM.</li>
</ol>
<p><span class="Bold">SOME SPECIAL ADVICE</span></p>
<ul>
<li>You may experience <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span> when using LUPRON INJECTION (leuprolide acetate).  During the first few weeks of treatment you may experience increased <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span>, increased difficulty in urinating, and less commonly but most importantly, you may experience the onset or aggravation of nerve symptoms.  In any of these events, discuss the symptoms with your doctor.  Like other treatment options, LUPRON may cause <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>.  Notify your doctor if you develop new or worsened symptoms after beginning LUPRON treatment.</li>
<li>You may experience some irritation at the injection site, such as burning, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>. These reactions are usually mild and go away.  If they do not, tell your doctor.</li>
<li>If you have experienced an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to other drugs like LUPRON, you should not use this drug.</li>
<li>Do not stop taking your injections because you feel better.  You need an injection every day to make sure LUPRON keeps working for you.</li>
<li>If you need to use an alternate to the syringe supplied with LUPRON, low-dose insulin syringes should be utilized.</li>
<li>When the drug level gets low, take special care to hold the bottle straight up and down and to keep the needle tip in liquid while pulling back on the plunger.</li>
<li>Do not try to get every last drop out of the bottle. This will increase the possibility of drawing air into the syringe and getting an incomplete dose.  Some extra drug has been provided so that you can withdraw the recommended number of doses.</li>
<li>Tell your pharmacist when you will need LUPRON so it will be at the pharmacy when you need it.</li>
<li>Store below 77°F (25°C).  Do not store near a radiator or other very warm place.  Do not freeze.  Protect from light; store vial in carton until use.</li>
<li>Do not leave your drug or hypodermic syringes where anyone can pick them up.</li>
<li>Keep this and all other medications out of reach of children.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<h1></h1>
<p class="First">Manufactured for<br>TAP Pharmaceuticals Inc.<br>Lake Forest, IL 60045, U.S.A.</p>
<p>® – Registered<br>(No. 3612)<br>03-A066-R7; December 2007<br>© 1993 – 2007 TAP Pharmaceutical Products Inc.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="For_Ped_Use"></a><a name="section-17"></a><p></p>
<h1>For Pediatric Use</h1>
<p class="First"><span class="Bold">LUPRON<span class="Sup">®</span> INJECTION</span><br>(leuprolide acetate) </p>
<p><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-18"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Leuprolide acetate is a synthetic nonapeptide analog of naturally occurring gonadotropin releasing hormone (GnRH or LH-RH).  The analog possesses greater potency than the natural hormone.  The chemical name is 5- oxo -L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide acetate (salt) with the following structural formula:</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=319F0AF7-6CC7-4A91-A28A-9CEEA37D0CA8&amp;name=luproninjection-01.jpg"></div>
<p>LUPRON INJECTION is a sterile, aqueous solution intended for daily subcutaneous injection.</p>
<p>It is available in a 2.8 mL multiple dose vial containing leuprolide acetate (5 mg/mL), sodium chloride, USP (6.3 mg/mL) for tonicity adjustment, benzyl alcohol, NF as a preservative  (9 mg/mL), and water for injection, USP.  The pH may have been adjusted with sodium hydroxide, NF and/or acetic acid, NF.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Clinical_PharmacologyPed"></a><a name="section-19"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Leuprolide acetate, a GnRH agonist, acts as a potent inhibitor of gonadotropin secretion when given continuously and in therapeutic doses.  Animal and human studies indicate that following an initial stimulation of gonadotropins, chronic administration of leuprolide acetate results in suppression of ovarian and testicular steroidogenesis.  This effect is reversible upon discontinuation of drug therapy.</p>
<p>Leuprolide acetate is not active when given orally.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="PharmacokineticsPed"></a><a name="section-19.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">A pharmacokinetic study of leuprolide acetate in children has not been performed.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-19.1.1"></a><p></p>
<h3>Absorption </h3>
<p class="First">In adults, bioavailability by subcutaneous administration is comparable to that by intravenous administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-19.1.2"></a><p></p>
<h3>Distribution </h3>
<p class="First">The mean steady-state volume of distribution of leuprolide following intravenous bolus administration to healthy adult male volunteers was 27 L. <span class="Italics">In vitro</span> binding to human plasma proteins ranged from 43% to 49%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-19.1.3"></a><p></p>
<h3>Metabolism </h3>
<p class="First">In healthy adult male volunteers, a 1 mg bolus of leuprolide administered intravenously revealed that the mean systemic clearance was 7.6 L/h, with a terminal elimination half-life of approximately 3 hours based on a two compartment model.</p>
<p>In rats and dogs, administration of <span class="Sup">14</span>C-labeled leuprolide was shown to be metabolized to smaller inactive peptides, a pentapeptide (Metabolite I), tripeptides (Metabolites II and III) and a dipeptide (Metabolite IV). These fragments may be further catabolized.</p>
<p>The major metabolite (M-I) plasma concentrations measured in 5 prostate cancer patients reached maximum concentration 2 to 6 hours after dosing and were approximately 6% of the peak parent drug concentration. One week after dosing, mean plasma M-I concentrations were approximately 20% of mean leuprolide concentrations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-19.1.4"></a><p></p>
<h3>Excretion </h3>
<p class="First">Following administration of LUPRON DEPOT 3.75 mg to three adult patients, less than 5% of the dose was recovered as parent and M-I metabolite in the urine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-19.1.5"></a><p></p>
<h3>Special Populations </h3>
<p class="First">The pharmacokinetics of the drug in hepatically and renally impaired patients has not been determined.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-19.1.6"></a><p></p>
<h3>Drug Interactions </h3>
<p class="First">No pharmacokinetic-based drug-drug interaction studies have been conducted with leuprolide acetate. However, because leuprolide acetate is a peptide that is primarily degraded by peptidase and the drug is only about 46% bound to plasma proteins, drug interactions would not be expected to occur.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-20"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">In children with central <span class="product-label-link" type="condition" conceptid="4267558" conceptname="Precocious puberty">precocious puberty</span> (CPP), stimulated and basal gonadotropins are reduced to prepubertal levels. Testosterone and estradiol are reduced to prepubertal levels in males and females respectively. Reduction of gonadotropins will allow for normal physical and psychological growth and development. Natural maturation occurs when gonadotropins return to pubertal levels following discontinuation of leuprolide acetate.</p>
<p>The following physiologic effects have been noted with the chronic administration of leuprolide acetate in this patient population.</p>
<ol>
<li>
<span class="Bold">Skeletal Growth.</span> A measurable increase in body length can be noted since the epiphyseal plates will not close prematurely.</li>
<li>
<span class="Bold">Organ Growth.</span> Reproductive organs will return to a prepubertal state.</li>
<li>
<span class="Bold">Menses.</span> Menses, if present, will cease.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-21"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">LUPRON INJECTION is indicated in the treatment of children with central <span class="product-label-link" type="condition" conceptid="4267558" conceptname="Precocious puberty">precocious puberty</span>.  Children should be selected using the following criteria:</p>
<ol>
<li>Clinical diagnosis of CPP (idiopathic or neurogenic) with onset of secondary sexual characteristics earlier than 8 years in females and 9 years in males.</li>
<li>Clinical diagnosis should be confirmed prior to initiation of therapy: 							 							<ul class="Disc">
<li>Confirmation of diagnosis by a pubertal response to a GnRH stimulation test.  The sensitivity and methodology of this assay must be understood.</li>
<li>Bone age advanced 1 year beyond the chronological age.</li>
</ul>
</li>
<li>Baseline evaluation should also include: 							 							<ul class="Disc">
<li>Height and weight measurements.</li>
<li>Sex steroid levels.</li>
<li>Adrenal steroid level to exclude congenital adrenal <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>.</li>
<li>Beta human chorionic gonadotropin level to rule out a chorionic gonadotropin secreting tumor.</li>
<li>Pelvic/adrenal/testicular ultrasound to rule out a steroid secreting tumor.</li>
<li>Computerized tomography of the head to rule out intracranial tumor.</li>
</ul>
</li>
</ol>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ContraindicationsPed"></a><a name="section-22"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<ol>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to GnRH, GnRH agonist analogs or any of the excipients in LUPRON INJECTION. Reports of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> to GnRH agonist analogs have been reported in the medical literature.<span class="Sup">1,2</span>
</li>
<li>LUPRON is contraindicated in women who are or may become pregnant while receiving the drug. LUPRON may cause fetal harm when administered to a pregnant woman. Major fetal abnormalities were observed in rabbits but not in rats after administration of leuprolide acetate throughout gestation. There was increased fetal mortality and decreased fetal weights in rats and rabbits. (See <span class="Bold"><a href="#Teratogenic_EffectsPed">PRECAUTIONS, Pregnancy, Teratogenic Effects</a></span> section.) The effects on fetal mortality are expected consequences of the alterations in hormonal levels brought about by this drug. Therefore, the possibility exists that <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortion</span> may occur if the drug is administered during pregnancy. If this drug is administered during pregnancy or if the patient becomes pregnant while taking any formulation of LUPRON, the patient should be apprised of the potential hazard to the fetus.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="WarningsPed"></a><a name="section-23"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">During the early phase of therapy, gonadotropins and sex steroids rise above baseline because of the natural stimulatory effect of the drug.  Therefore, an increase in clinical signs and symptoms may be observed (see <span class="Bold"><a href="#Clinical_PharmacologyPed">CLINICAL PHARMACOLOGY</a></span> section).</p>
<p>Noncompliance with drug regimen or inadequate dosing may result in inadequate control of the pubertal process.  The consequences of poor control include the return of pubertal signs such as menses, breast development, and testicular growth.  The long-term consequences of inadequate control of gonadal steroid secretion are unknown, but may include a further compromise of adult stature.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="PrecautionsPed"></a><a name="section-24"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">Patients with known allergies to benzyl alcohol, an ingredient of the vehicle of LUPRON INJECTION, may present symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, usually local, in the form of <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> and <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span> at the injection site.</p>
<div class="Section" data-sectionCode="34076-0">
<a name="section-24.1"></a><p></p>
<h2>Information for Parents</h2>
<p class="First">Prior to starting therapy with LUPRON INJECTION, the parent or guardian must be aware of the importance of continuous therapy. Adherence to daily drug administration schedules must be accepted if therapy is to be successful.  Irregular dosing could restart the maturation process.</p>
<ul class="Disc">
<li>During the first 2 months of therapy, a female may experience menses or spotting. If <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> continues beyond the second month, notify the physician. </li>
<li>Any irritation at the injection site should be reported to the physician immediately. If the child has experienced an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to other drugs like LUPRON, this drug should not be used.</li>
<li>Report any unusual signs or symptoms to the physician, like continued pubertal changes, substantial <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span> or behavioral changes.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-24.2"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Response to leuprolide acetate should be monitored 1-2 months after the start of therapy with a GnRH stimulation test and sex steroid levels.  Measurement of bone age for advancement should be done every 6-12 months.</p>
<p>Sex steroids may increase or rise above prepubertal levels if the dose is inadequate (see <span class="Bold"><a href="#WarningsPed">WARNINGS</a></span> section).  Once a therapeutic dose has been established, gonadotropin and sex steroid levels will decline to prepubertal levels.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-24.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">See <span class="Bold"><a href="#PharmacokineticsPed">CLINICAL PHARMACOLOGY, Pharmacokinetics</a></span> section.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section-24.4"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">Administration of leuprolide acetate in therapeutic doses results in suppression of the pituitary-gonadal system.  Normal function is usually restored within 4 to 12 weeks after treatment is discontinued.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-24.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">A two-year carcinogenicity study was conducted in rats and mice. In rats, a dose-related increase of benign pituitary <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> and benign <span class="product-label-link" type="condition" conceptid="437251" conceptname="Benign neoplasm of pituitary gland and craniopharyngeal duct">pituitary adenomas</span> was noted at 24 months when the drug was administered subcutaneously at high daily doses of 0.6 to 4 mg/kg (&gt;100 times the clinical doses of 7.5 to 15 mg/month based on body surface area). There was a significant but not dose-related increase of pancreatic islet-cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in females and of testes interstitial cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in males (highest incidence in the low dose group). In mice, no leuprolide acetate-induced tumors or pituitary abnormalities were observed at daily dose as high as 60 mg/kg (&gt;5000 times the clinical doses based on body surface area). Adult patients have been treated with leuprolide acetate for up to three years with doses as high as 10 mg/day and for two years with doses as high as 20 mg/day without demonstrable pituitary abnormalities.</p>
<p>Although no clinical studies have been completed in children to assess the full reversibility of fertility suppression, animal studies (prepubertal and adult rats and monkeys) with leuprolide acetate and other GnRH analogs have shown functional recovery.  However, following a study with leuprolide acetate, immature male rats demonstrated tubular degeneration in the testes even after a recovery period. In spite of the failure to recover histologically, the treated males proved to be as fertile as the controls. Also, no histologic changes were observed in the female rats following the same protocol. In both sexes, the offspring of the treated animals appeared normal.  The effect of the treatment of the parents on the reproductive performance of the F1 generation was not tested. The clinical significance of these findings is unknown.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-24.6"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="Teratogenic_EffectsPed"></a><a name="section-24.6.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-24.6.1.1"></a><p></p>
<h4>Pregnancy Category X</h4>
<p class="First">(see <span class="Bold"><a href="#ContraindicationsPed">CONTRAINDICATIONS</a></span> section)</p>
<p>When administered on day 6 of pregnancy at test dosages of 0.00024, 0.0024, and 0.024 mg/kg (1/1200 to 1/12 the human pediatric dose) to rabbits, LUPRON produced a dose-related increase in major fetal abnormalities. Similar studies in rats failed to demonstrate an increase in <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span>. There was increased fetal mortality and decreased fetal weights with the two higher doses of LUPRON in rabbits and with the highest dose in rats.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-24.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether leuprolide acetate is excreted in human milk. LUPRON should not be used by nursing mothers.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-24.8"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">See labeling for LUPRON INJECTION for the pharmacokinetics, efficacy and safety of LUPRON in this population.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-25"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-25.1"></a><p></p>
<h2>Clinical Trials</h2>
<p class="First">Potential exacerbation of signs and symptoms during the first few weeks of treatment (see <span class="Bold"><a href="#PrecautionsPed">PRECAUTIONS</a></span> section) is a concern in patients with rapidly advancing central <span class="product-label-link" type="condition" conceptid="4267558" conceptname="Precocious puberty">precocious puberty</span>.</p>
<p>In two studies of children with central <span class="product-label-link" type="condition" conceptid="4267558" conceptname="Precocious puberty">precocious puberty</span>, in 2% or more of the patients receiving the drug, the following adverse reactions were reported to have a possible or probable relationship to drug as ascribed by the treating physician.  Reactions considered not drug related are excluded.</p>
<table width="80%">
<col align="left" width="50%">
<col align="center" width="20%">
<col align="center" width="20%">
<thead><tr class="First Last">
<th align="left"></th>
<th align="center" colspan="2">
<span class="Underline">Number of Patients</span><br><span class="Underline">N = 395 (Percent)</span>
</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left">Body as a Whole</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  General <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td align="center">7</td>
<td align="center">(2)</td>
</tr>
<tr>
<td align="left">Integumentary System</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span>/<span class="product-label-link" type="condition" conceptid="138821" conceptname="Seborrhea">Seborrhea</span></td>
<td align="center">7</td>
<td align="center">(2)</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection Site Reactions</span> Including <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">Abscess</span></td>
<td align="center">21</td>
<td align="center">(5)</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> Including <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">Erythema Multiforme</span></td>
<td align="center">8</td>
<td align="center">(2)</td>
</tr>
<tr>
<td align="left">Urogenital System</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr class="Last">
<td align="left">  <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">Vaginitis</span>/<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>/ Discharge</td>
<td align="center">7</td>
<td align="center">(2)</td>
</tr>
</tbody>
</table>
<p>In those same studies, the following adverse reactions were reported in less than 2% of the patients.</p>
<p><span class="Italics">Body as a Whole -</span> <span class="product-label-link" type="condition" conceptid="4178504" conceptname="Body odor">Body Odor</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>; <span class="Italics">Cardiovascular System -</span> <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>, Vasodilation; <span class="Italics">Digestive System -</span> <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4281516" conceptname="Gingivitis">Gingivitis</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>; <span class="Italics">Endocrine System -</span> <span class="product-label-link" type="condition" conceptid="4267558" conceptname="Precocious puberty">Accelerated Sexual Maturity</span>; <span class="Italics">Metabolic and Nutritional Disorders -</span> <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral Edema</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span>; <span class="Italics">Nervous System -</span> <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span>, <span class="product-label-link" type="condition" conceptid="441838" conceptname="Personality disorder">Personality Disorder</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">Emotional Lability</span>; <span class="Italics">Respiratory System -</span> <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span>; <span class="Italics">Integumentary System -</span> <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>, <span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">Skin Striae</span>; <span class="Italics">Urogenital System -</span> <span class="product-label-link" type="condition" conceptid="194088" conceptname="Hypertrophic elongation of cervix">Cervix Disorder</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span>/<span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">Urinary Incontinence</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-25.2"></a><p></p>
<h2>Postmarketing </h2>
<p class="First">During postmarketing surveillance, which includes other dosage forms and other patient populations, the following adverse events were reported.</p>
<p>Symptoms consistent with an anaphylactoid or <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> process have been rarely (incidence rate of about 0.002%) reported. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reactions</span> have also been reported. Localized reactions including <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span> and <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span> have been reported at the site of injection. Symptoms consistent with <span class="product-label-link" type="condition" conceptid="442315" conceptname="Fibrositis">fibromyalgia</span> (e.g., joint and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorders</span>, gastrointestinal distress, and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>) have been reported individually and collectively.</p>
<p><span class="Italics">Cardiovascular System</span> – <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span>; <span class="Italics">Gastrointestinal System</span> – Hepatic dysfunction; <span class="Italics">Hemic and Lymphatic System</span> – Decreased WBC; <span class="Italics">Integumentary System</span> – Hair growth; <span class="Italics">Central/Peripheral Nervous System</span> – <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">Spinal fracture</span>/<span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>, Hearing disorder; <span class="Italics">Miscellaneous</span> – Hard <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodule</span> in throat, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span>, Increased uric acid; <span class="Italics">Musculoskeletal System</span> – <span class="product-label-link" type="condition" conceptid="4195698" conceptname="Tenosynovitis">Tenosynovitis</span>-like symptoms; <span class="Italics">Respiratory System</span> – <span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory disorders</span>; <span class="Italics">Urogenital System</span> – Prostate <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-25.2.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics">Changes in Bone Density:</span> Decreased bone density has been reported in the medical literature in men who have had orchiectomy or who have been treated with an LH-RH agonist analog. In a clinical trial, 25 men with prostate cancer, 12 of whom had been treated previously with leuprolide acetate for at least six months, underwent bone density studies as a result of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. The leuprolide-treated group had lower bone density scores than the nontreated control group. The effects on bone density in children are unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-25.2.2"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4129534" conceptname="Pituitary apoplexy">Pituitary apoplexy</span>:</span> During post-marketing surveillance, rare cases of <span class="product-label-link" type="condition" conceptid="4129534" conceptname="Pituitary apoplexy">pituitary apoplexy</span> (a clinical syndrome secondary to <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> of the pituitary gland) have been reported after the administration of gonadotropin-releasing hormone agonists.  In a majority of these cases, a <span class="product-label-link" type="condition" conceptid="437251" conceptname="Benign neoplasm of pituitary gland and craniopharyngeal duct">pituitary adenoma</span> was diagnosed, with a majority of <span class="product-label-link" type="condition" conceptid="4129534" conceptname="Pituitary apoplexy">pituitary apoplexy</span> cases occurring within 2 weeks of the first dose, and some within the first hour.  In these cases, <span class="product-label-link" type="condition" conceptid="4129534" conceptname="Pituitary apoplexy">pituitary apoplexy</span> has presented as sudden <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, visual changes, <span class="product-label-link" type="condition" conceptid="4052337" conceptname="Ophthalmoplegia">ophthalmoplegia</span>, altered mental status, and sometimes <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>.  Immediate medical attention has been required.</p>
<p>See other LUPRON INJECTION and LUPRON DEPOT package inserts for adverse events reported in other patient populations.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-26"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">In rats, subcutaneous administration of 125 to 250 times the recommended human pediatric dose, expressed on a per body weight basis, resulted in <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4139968" conceptname="Underactive">decreased activity</span>, and local irritation at the injection site.  There is no evidence at present that there is a clinical counterpart of this phenomenon. In early clinical trials using leuprolide acetate in adult patients, doses as high as 20 mg/day for up to two years caused no adverse effects differing from those observed with the 1 mg/day dose.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-27"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">LUPRON INJECTION can be administered by a patient/parent or health care professional.</p>
<p>The dose of LUPRON INJECTION must be individualized for each child.  The dose is based on a mg/kg ratio of drug to body weight.  Younger children require higher doses on a mg/kg ratio.</p>
<p>After 1-2 months of initiating therapy or changing doses, the child must be monitored with a GnRH stimulation test, sex steroids, and Tanner staging to confirm downregulation. Measurements of bone age for advancement should be monitored every 6-12 months. The dose should be titrated upward until no progression of the condition is noted either clinically and/or by laboratory parameters.</p>
<p>The first dose found to result in adequate downregulation can probably be maintained for the duration of therapy in most children.  However, there are insufficient data to guide dosage adjustment as patients move into higher weight categories after beginning therapy at very young ages and low dosages. It is recommended that adequate downregulation be verified in such patients whose weight has increased significantly while on therapy.</p>
<p>As with other drugs administered by injection, the injection site should be varied periodically.</p>
<p>Discontinuation of LUPRON INJECTION should be considered before age 11 for females and age 12 for males.</p>
<p>The recommended starting dose is 50 mcg/kg/day administered as a single subcutaneous injection.  If total downregulation is not achieved, the dose should be titrated upward by 10 mcg/kg/day.  This dose will be considered the maintenance dose.</p>
<p>Follow the pictorial directions on the reverse side of this package insert for administration.</p>
<p>NOTE:  As with other parenteral products, inspect the solution for discoloration and particulate matter before each use.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-28"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">LUPRON INJECTION (leuprolide acetate) is a sterile solution supplied in a 2.8 mL multiple-dose vial.  The vial is packaged as follows:</p>
<ul class="Disc">
<li>14 Day Patient Administration Kit with 14 disposable syringes and 28 alcohol swabs, NDC 0300-3612-28.</li>
<li>Six-vial carton, NDC 0300-3612-24.</li>
<li>Store below 77°F (25°C). Do not freeze.  Protect from light; store vial in carton until use.</li>
<li>Use the syringes supplied with LUPRON INJECTION.  Insulin syringes may be substituted for use with LUPRON INJECTION.</li>
</ul>
<p>U.S. Patent Nos. 4,005,063; 4,005,194.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-29"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>Taylor, JD. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reaction</span> to LHRH analogue, leuprorelin. <span class="Italics">Med J Australia</span> 1994 Oct; 161(3): 455.</li>
<li>Letterie GS, <span class="Italics">et al</span>. Recurrent <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> to a depot form of GnRH analogue. <span class="Italics">Obstet Gynecol</span> 1991 Nov; 78: 943–946.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-30"></a><p></p>
<p class="First">Manufactured for<br>TAP Pharmaceuticals Inc.<br>Lake Forest, IL 60045, U.S.A.</p>
<p>® – Registered </p>
<p>(No. 3612)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-31"></a><p></p>
<h1>ADMINISTERING THE INJECTION</h1>
<p class="First"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=319F0AF7-6CC7-4A91-A28A-9CEEA37D0CA8&amp;name=luproninjection-02.jpg"></p>
<p>Read this booklet before injecting the medication. Read the complete instructions for injection.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-32"></a><p></p>
<h1></h1>
<p class="First">TAP Pharmaceutical Products Inc.<br>Lake Forest, IL 60045, U.S.A.</p>
<p>(No. 3612)<br>03-A066 R7; December 2007</p>
<p>© 1993–2007 TAP Pharmaceutical Products Inc.</p>
<p>Provided as an educational service by<br>TAP Pharmaceuticals Inc.</p>
<p>TAP Pharmaceutical Products Inc.<br>Lake Forest, IL 60045, U.S.A.</p>
<p>[Bar code 128 of commodity number]</p>
</div>
<div class="Section" data-sectionCode="38056-8">
<a name="section-33"></a><p></p>
<div class="Section" data-sectionCode="42230-3">
<a name="section-33.1"></a><p></p>
<h2>ADMINISTERING THE INJECTION</h2>
<p class="First"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=319F0AF7-6CC7-4A91-A28A-9CEEA37D0CA8&amp;name=luproninjection-03.jpg"></p>
<dl>
<dt class="Bold">1. </dt>
<dd>
<span class="Bold">Wash hands thoroughly.</span><p class="First"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=319F0AF7-6CC7-4A91-A28A-9CEEA37D0CA8&amp;name=luproninjection-04.jpg"></p>
</dd>
<dt class="Bold">2. </dt>
<dd>
<span class="Bold">Check the liquid in the container. It should look clear. DO NOT USE if it is not clear or if it has particles in it. If using a new bottle, flip off the plastic cover to expose the grey rubber stopper. Use an alcohol swab to cleanse the metal ring and rubber stopper on medication bottle every day, just before you use it. </span><p class="First"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=319F0AF7-6CC7-4A91-A28A-9CEEA37D0CA8&amp;name=luproninjection-05.jpg"></p>
</dd>
<dt class="Bold">3. </dt>
<dd>
<span class="Bold">Remove outer wrapping from one syringe. </span><p class="First"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=319F0AF7-6CC7-4A91-A28A-9CEEA37D0CA8&amp;name=luproninjection-06.jpg"></p>
</dd>
<dt class="Bold">4. </dt>
<dd>
<span class="Bold">Pull the syringe plunger back until its tip is at the proper mark.</span><p class="First"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=319F0AF7-6CC7-4A91-A28A-9CEEA37D0CA8&amp;name=luproninjection-07.jpg"></p>
</dd>
<dt class="Bold">5. </dt>
<dd>
<span class="Bold">Uncover needle. Do not touch the needle.</span><p class="First"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=319F0AF7-6CC7-4A91-A28A-9CEEA37D0CA8&amp;name=luproninjection-08.jpg"></p>
</dd>
<dt class="Bold">6. </dt>
<dd>
<span class="Bold">Place the bottle on a clean, flat surface and push the needle 	through the center of the rubber stopper on the bottle. Push the plunger all the way in to inject air into the bottle.</span><p class="First"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=319F0AF7-6CC7-4A91-A28A-9CEEA37D0CA8&amp;name=luproninjection-09.jpg"></p>
</dd>
<dt class="Bold">7. </dt>
<dd>
<span class="Bold">Keep the needle in the bottle. <br>Lift the bottle and turn it straight upside down. <br>Check to see that the needle tip is in the liquid.</span><p class="First"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=319F0AF7-6CC7-4A91-A28A-9CEEA37D0CA8&amp;name=luproninjection-10.jpg"></p>
</dd>
<dt class="Bold">8. </dt>
<dd>
<span class="Bold">With the needle tip in the liquid, slowly pull back the plunger until syringe fills to the proper mark.<br>If any bubbles appear in the syringe, remove them by pushing the plunger up slowly. <br>With the needle tip still in the liquid, pull the plunger until it is once more at the proper mark.</span><p class="First"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=319F0AF7-6CC7-4A91-A28A-9CEEA37D0CA8&amp;name=luproninjection-11.jpg"></p>
</dd>
<dt class="Bold">9. </dt>
<dd>
<span class="Bold">Choose a different injection site each day.<br>	Cleanse the injection site with a new alcohol swab.<br>	Hold the skin the way you were instructed.<br>	Slide the needle quickly all the way through the skin, into the subcutaneous tissue, at a 90° angle.</span><p class="First"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=319F0AF7-6CC7-4A91-A28A-9CEEA37D0CA8&amp;name=luproninjection-12.jpg"></p>
</dd>
<dt class="Bold">10. </dt>
<dd>
<span class="Bold">Push the plunger to inject the medication.<br>	 Withdraw the needle at the same angle it was inserted (90°).<br>	 Wipe the skin with an alcohol swab.</span><p class="First"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=319F0AF7-6CC7-4A91-A28A-9CEEA37D0CA8&amp;name=luproninjection-13.jpg"></p>
</dd>
<dt class="Bold">11. </dt>
<dd><span class="Bold">Dispose of the syringe and alcohol swabs as you were instructed.<br>Remember: use the disposable syringe only once.</span></dd>
</dl>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LUPRON  		
					</strong><br><span class="contentTableReg">leuprolide acetate kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0300-3612</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0300-3612-28</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1  </td>
<td class="formItem">2.8 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">28  </td>
<td class="formItem">28 </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>LUPRON 		
					</strong><br><span class="contentTableReg">leuprolide acetate injection, solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>leuprolide acetate</strong> (leuprolide) </td>
<td class="formItem"></td>
<td class="formItem">5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem">6.3 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>benzyl alcohol</strong></td>
<td class="formItem">9 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>acetic acid,</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0300-3612-28</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2.8 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>ALCOHOL 		
					</strong><br><span class="contentTableReg">alcohol swab</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Alcohol</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 PACKET</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LUPRON 		
					</strong><br><span class="contentTableReg">leuprolide acetate injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0300-3612</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>leuprolide acetate</strong> (leuprolide) </td>
<td class="formItem"></td>
<td class="formItem">5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem">6.3 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>benzyl alcohol</strong></td>
<td class="formItem">9 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>acetic acid</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0300-3612-24</td>
<td class="formItem">6  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2.8 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>TAP Pharmaceutical Products Inc.</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 2/2008<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>3A1CFED7-1D55-89DB-2FCB-03EDBE0E19A8</div>
<div>Set id: 319F0AF7-6CC7-4A91-A28A-9CEEA37D0CA8</div>
<div>Version: 1</div>
<div>Effective Time: 20080229</div>
</div>
</div> <div class="DistributorName">TAP Pharmaceutical Products Inc.</div></p>
</body></html>
